Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Urol Oncol. 2022 Feb;40(2):63.e9-63.e18. doi: 10.1016/j.urolonc.2021.06.021. Epub 2021 Jul 28.
Molecular markers associated with breast cancer are assumed to be associated with outcome in non-muscle-invasive bladder cancer (NMIBC).
We retrospectively investigated the association of the mRNA expression of estrogen receptor 1 (ESR1) and 2 (ESR2), progesterone receptor (PGR), MKI67, and HER2 (ERBB2) with recurrence-free (RFS), cancer-specific (CSS), and overall survival (OS) in 80 patients with stage T1 NMIBC.
High expression of ESR2 (P = 0.003), ERBB2 (P < 0.001), and MKI67 (P = 0.029) was associated with shorter RFS. Only high ERBB2 was an independent prognostic factor for reduced RFS (HR = 2.98; P = 0.009). When sub stratifying the cohort, high ESR2 was associated with reduced RFS (P < 0.001), CSS (P = 0.037) and OS (P = 0.006) in patients without instillation therapy. High ESR2 was associated with reduced CSS (P = 0.018) and OS (P = 0.029) in females and with shorter RFS in both sexes (males: P = 0.035; females: P = 0.010). Patients with high ERBB2 showed reduced CSS (P = 0.011) and OS (P = 0.042) in females and reduced CSS (P = 0.012) in those without instillation, while RFS was significantly reduced irrespective of sex or instillation.
High mRNA expression of ERBB2 is an independent predictor of reduced RFS in patients with stage T1 NMIBC. High ERBB2 and ESR2 are associated with reduced outcomes, especially in females and patients without instillation therapy.
与乳腺癌相关的分子标志物被认为与非肌肉浸润性膀胱癌（NMIBC）的结局相关。
我们回顾性调查了 80 例 T1 期 NMIBC 患者中雌激素受体 1（ESR1）和 2（ESR2）、孕激素受体（PGR）、MKI67 和 HER2（ERBB2）mRNA 表达与无复发生存（RFS）、癌症特异性（CSS）和总生存（OS）的关系。
ESR2（P=0.003）、ERBB2（P<0.001）和 MKI67（P=0.029）高表达与 RFS 缩短相关。只有高 ERBB2 是 RFS 降低的独立预后因素（HR=2.98；P=0.009）。当对队列进行分层时，在未接受灌注治疗的患者中，高 ESR2 与 RFS 降低（P<0.001）、CSS（P=0.037）和 OS（P=0.006）相关。在女性中，高 ESR2 与 CSS（P=0.018）和 OS（P=0.029）降低相关，在两性中均与 RFS 缩短相关（男性：P=0.035；女性：P=0.010）。在女性中，高 ERBB2 患者的 CSS（P=0.011）和 OS（P=0.042）降低，在未接受灌注治疗的患者中 CSS（P=0.012）降低，而 RFS 无论性别或灌注如何均显著降低。
在 T1 期 NMIBC 患者中，高 ERBB2 mRNA 表达是 RFS 降低的独立预测因子。高 ERBB2 和 ESR2 与结局降低相关，尤其是在女性和未接受灌注治疗的患者中。
